Introgen Therapeutics, Inc.
301 Congress Avenue, Suite 1850
Austin
Texas
78701
United States
Tel: 512-320-5010
Fax: 512-320-4166
Website: http://www.introgen.com/
128 articles about Introgen Therapeutics, Inc.
-
Introgen Therapeutics, Inc. Announces Resignation of David G. Nance from Board of Directors
3/12/2009
-
Introgen Therapeutics, Inc. Common Stock to be Delisted from the Nasdaq Stock Market
12/8/2008
-
Introgen Therapeutics, Inc. Restructures Operations to Focus on Revenue-Generating Manufacturing Capabilities; Reduces Staff
12/1/2008
-
Introgen Therapeutics, Inc. Announces the Transfer of its Listing of Common Stock from the Nasdaq Global Market to the Nasdaq Capital Market
11/19/2008
-
Introgen Therapeutics, Inc. Hires An Adviser To Pursue Strategic Options, Including A Possible Sale
11/12/2008
-
Introgen Therapeutics, Inc. Reports Third Quarter 2008 Financial Results
11/11/2008
-
Introgen Therapeutics, Inc. Receives Notification From NASDAQ
10/6/2008
-
Introgen Therapeutics, Inc. Receives Staff Determination Letter from Nasdaq Global Market
9/8/2008
-
Introgen Therapeutics, Inc. Sell-Off Continues
9/4/2008
-
Introgen Therapeutics, Inc. Receives Notice ADVEXIN(R) U.S. BLA Not Sufficiently Complete to File
9/2/2008
-
Introgen Therapeutics, Inc.'s ADVEXIN(R) MAA Accepted for Review by European Medicines Evaluation Agency
8/18/2008
-
Introgen Therapeutics, Inc. Appoints James E. Rothman, Ph.D., to Board of Directors
8/12/2008
-
Introgen Therapeutics, Inc. Reports Second Quarter 2008 Financial Results and Recent Corporate Highlights
8/7/2008
-
Introgen Therapeutics, Inc. Receives Nasdaq Notice Regarding Minimum Market Value of Listed Securities
8/4/2008
-
Introgen Therapeutics, Inc. Release: ADVEXIN(R) Shows Statistically Significant Six-Month and Overall Survival Benefit as Compared to Methotrexate in Prospectively Defined Biomarker Patient Population
7/23/2008
-
Introgen Therapeutics, Inc. to Present ADVEXIN Phase 3 Study Results at American Association for Cancer Research's Cancer Clinical Trials and Personalized Medicine Conference
7/17/2008
-
Introgen Therapeutics, Inc.'s Flagship Cancer Drug Advexin Questioned
7/15/2008
-
Introgen Therapeutics, Inc. Cuts 29% of Jobs as it Moves to Market Cancer Therapy
7/15/2008
-
Introgen Therapeutics, Inc. to Host Conference Call with Clinical Investigators to Discuss Phase III Data and ADVEXIN Registration Activities
7/9/2008
-
Introgen Therapeutics, Inc. Cuts 29% of Jobs as it Moves to Market Cancer Therapy
7/7/2008